08.24.12
Pfizer has terminated its three-year supply agreement with Claris Lifesciences, based in Ahmedabad, India. "Pfizer has terminated its supply agreement and has no current plans to source any products from Claris," a Pfizer spokesperson said.
Pfizer and Claris entered the agreement in 2009 giving Claris access to markets in North America, Europe and Australia. Under the agreement, Pfizer sold 15 generic parenteral products made by Claris under the Pfizer brand name.
In 2010, the FDA issued a warning to Claris regarding quality issues and banned the sale of its products in the U.S. until compliance issues were resolved. The FDA lifted the ban earlier this week following a facility inspection in February.
In March, Pfizer ended an agreement with Bangalore-based Biocon to sell its insulin products. Pfizer has ongoing supply agreements with Hyderabad-based Aurobindo Pharma and Bangalore-based Strides Arcolab.
Pfizer and Claris entered the agreement in 2009 giving Claris access to markets in North America, Europe and Australia. Under the agreement, Pfizer sold 15 generic parenteral products made by Claris under the Pfizer brand name.
In 2010, the FDA issued a warning to Claris regarding quality issues and banned the sale of its products in the U.S. until compliance issues were resolved. The FDA lifted the ban earlier this week following a facility inspection in February.
In March, Pfizer ended an agreement with Bangalore-based Biocon to sell its insulin products. Pfizer has ongoing supply agreements with Hyderabad-based Aurobindo Pharma and Bangalore-based Strides Arcolab.